Beta Bionics (BBNX) director receives 3,997 RSUs under 2025 plan

Rhea-AI Filing Summary

Beta Bionics, Inc. director Sean Carney reported a stock-based award. On 01/13/2026, he acquired 3,997 shares of common stock at a price of $0, described as a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. After this grant, he beneficially owned 15,244 shares of Beta Bionics common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARNEY SEAN

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		A		3,997(1)	A	$0	15,244	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) disclose about director Sean Carney in this Form 4?

The filing shows that director Sean Carney acquired 3,997 shares of Beta Bionics common stock on 01/13/2026 through a restricted stock unit award under the company’s 2025 Equity Incentive Plan.

How many Beta Bionics shares did Sean Carney acquire in the latest transaction?

Sean Carney acquired 3,997 shares of Beta Bionics common stock, recorded with transaction code “A” for an acquisition and a price of $0 per share.

What is Sean Carney’s total Beta Bionics share ownership after this award?

After the reported transaction, Sean Carney beneficially owned 15,244 shares of Beta Bionics common stock.

Is the Beta Bionics insider transaction a sale or an award of shares?

The transaction is an award of shares. The Form 4 notes that the 3,997 shares represent a restricted stock unit award granted under the 2025 Equity Incentive Plan, with a reported price of $0 per share.

Does Sean Carney hold his Beta Bionics shares directly or indirectly?

The Form 4 reports his ownership as direct (D), and there is no indication in the footnotes that the shares are held through another entity.

What plan was used for the restricted stock unit award to Sean Carney at Beta Bionics?

The 3,997-share award is described as a restricted stock unit award granted under Beta Bionics’ 2025 Equity Incentive Plan.